

Gibson Dunn Advising Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent \$200 Million Financings

Firm News | December 17, 2025

Gibson Dunn is advising Yarrow Bioscience on its merger with VYNE Therapeutics and concurrent \$200 million financings.

Our corporate team includes partners Ryan Murr, Melanie Neary, and Branden Berns and associates Evan Shepherd and Candice Johnson.

Related People

[Ryan A. Murr](#)

[Melanie E. Neary](#)

[Branden C. Berns](#)

[Evan Shepherd](#)

[Candice D. Johnson](#)

Related Capabilities

[Life Sciences](#)

[Mergers and Acquisitions](#)